Chitin oligomers and polyunsaturated fatty acids act synergistically in inducing resistance in pearl millet against downy mildew disease by Geetha, N. P. et al.





   
 
Pelagia Research Library 
 





ISSN: 0976-8688  
CODEN (USA): PSHIBD 
 
141 
Pelagia Research Library 
Preparation, evaluation and bioavailability studies of Indomethacin 
loaded PEA polymeric microspheres for controlled drug delivery 
 
Manjunatha M1., Jagadish R.L1., *Gowda D.Vishakante.2, Mohammed S. Khan2 
 
1Department of Studies in Polymer Science, Mysore University, Mandya. 





The goal of any drug delivery system is to provide a therapeutic amount of drug (s) to the proper 
site in the body in order to promptly achieve and thereby to maintain the desired drug 
concentrations during treatment. This idealized objective can be achieved by targeting the drugs 
to a specific organ or tissue with the help of controlling the release rate of the drug during the 
transit time in gastro intestinal tract. The present study aims to the preparation of poly ester 
amide (PEA) microspheres containing indomethacin (IM) as a model drug, and to compare the 
In vitro release and pharmacokinetics of prepared IM formulations with commercially available 
Microcid®SR. In the present study, water is used to prepare PEA polymer microspheres by 
meltable dispersed emulsified cooling induced solidification method. Surface morphology of 
prepared microspheres has been evaluated using scanning electron microscopy (SEM). The SEM 
images revealed the spherical shape of microspheres with size ranges132 µm to 796 µm. 
Differential scanning calorimetry (DSC) and Fourier transform infrared (FTIR) spectroscopy 
studies indicated that the drug after encapsulation with PEA polymer was stable and compatible. 
A single dose randomized complete cross over study of IM (75mg) microspheres was carried out 
in healthy albino rabbits. Plasma IM concentrations and other pharmacokinetic parameters 
were statistically analyzed.   
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INTRODUCTION 
 
Oral route has been the most popular and successfully used for sustained delivery of drugs 
because of convenience and ease of administration, greater flexibility in dosage form design and 
ease of production and low cost of such a system. The growing interest in controlled drug 
delivery release is because of its benefits like increased patient compliance due to reduced 
frequency of administration and less undesirable side effects. Microencapsulation of drugs in a 
hydrophobic matrix such as polymer, control the release of drugs. The term “control” includes 
phenomena such as protection and masking, reduced dissolution rate, facilitation of handling and 
spatial targeting of the active ingredient. The characteristics of microspheres containing drug 
should be correlated with the required therapeutic action and are dictated by the materials and 
methods employed in the manufacture of the delivery systems. Different poly (ester) amides 
(PEA) polymers have been used as barrier coatings due to their hydrophobic nature. Oral 
controlled release dosage forms such as micro particles are becoming more popular than single 
unit dosage forms. The uniform distribution of these multiple unit dosage forms along the gastro 
intestinal tract could result in more reproducible drug absorption and reduced risk of local 
irritation. 
 
Poorly water-soluble drugs, which are lipophilic in nature easily, mix with PEA polymer and 
show good absorption rate. The PEA polymeric materials used in the current study have good 
pharmaceutical and biological properties. Different strategies have been developed in recent 
years to design different types PEA polymer microspheres loaded with hydrophilic and lipophilic 
drugs using toxic solvents. The use of such solvents during formulation is of environmental 
concern and challenges to human safety. To overcome this problem, in the present study, water is 
used to prepare PEA polymer microspheres by meltable dispersed emulsified cooling induced 
solidification method. Furthermore the process was optimized to produce microspheres to give 
better yield with spherical geometry and predictable dissolution pattern. Various drugs are 
loaded with PEA, which will delay the action, due to slow dissolution of the drug. Recently it has 
been reported that lipid soluble drugs gives better absorption if they are embedded in PEA 
polymer microspheres. Since dissolution is an important prerequisite for drug absorption in most 
of acidic or basic drugs, the used carriers influence the drug absorption to a great extent [1-3]. 
This write up will highlight a systematic study of the PEA microspheres to develop controlled 
drug delivery systems.                                         
 
Factors affecting the release of drugs from PEA polymer microspheres are as follows, [4] 
 
1. Molecular weight of the drug 
2. Physicochemical properties of the drug 
3. Type and amount of PEA polymer material used 
4. Size and density of the microspheres 
5. Presence of adjuvants 
6. pH of the dissolution medium 
7. Presence of enzymes  
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PEA polymer has been used as drug carriers to achieve controlled drug delivery for the past few 
decades. However PEA polymer microspheres have gained prominent interest owing to their 
versatile properties such as non immunogenic, biodegradable and capacity to encapsulate drugs.  
Indomethacin was chosen as a model drug. It is a drug of choice for maniac disease due to its 
narrow therapeutic index; a controlled release dosage form is highly desirable [5]. 
 
MATERIALS AND METHODS 
 
Indomethacin (IM), pure drug was kindly donated by Micro Labs (Banglore, India). White to 
pale yellow, crystalline powder, odorless. Practically insoluble in water.  
All other chemicals and reagents used were of analytical grade. 
 
Preparation of PEA microspheres 
Required quantity of PEA polymer was melted at a temperature at 265º C for 5 min separately in 
a water bath. Lithium carbonate (LC) which was already passed through sieve No.100 was 
dispersed in the melted PEA polymer mass and stirred for 30 min to obtain a homogeneous melt. 
These individual mixtures were poured into 150 ml of buffer solutions (pH 4.2 pthalate buffer, to 
minimize the solubility of drug) previously heated to a temperature (90ºC). Surfactant Tween 80 
(1.8%w/w) was added to the mixture. The whole mixture was mechanically stirred using a stirrer 
(RQ-127A) fitted with a four blade impeller of approximately 53mm diameter. The molten mass 
produces spherical particles due to dispersion in the aqueous medium. The mixture was stirred 
continuously at 90ºC for 2 minutes. After 2 minutes the temperature of the mixture in the beakers 
was cooled rapidly and brought down to 10OC by the addition of cool water.  The resultant solid 
spheres collected by filtration were extensively washed with water to remove any drug and 
surfactant residues. Air-drying at room temperature for 48 hours gave discrete, solid free flowing 
microspheres.  
A total of four formulations were prepared by varying polymer to drug ratio. 
 
Characterization of Microspheres 
Size distribution and size analysis:  Size distribution of the PEA microspheres were studied by 
sieve analysis technique. The separations of the microspheres into various size fractions were 
carried out. Drug loaded microspheres (10g) were placed on the top of series of six standard 
bronze sieves in the range of 1000 - 106 µm (Test sieves, India), arranged in the order of 
decreasing aperture size. The sieves were mounted on mechanical sieve shaker (C.M 
equipments, India) and operated for a period of 30 min, which is adequate for complete 
separation. 
 
Micromeritics properties:   
Tap density of prepared PEA microspheres was determined using tap density tester and 
percentage Carr’s index (%I) was calculated using the formula: 
 
Carr;s index (%I)= (tapped density-bulk density)/ tapped density  [1] 
 
Angle of repose (θ) was done in order to know the flow ability of PEA microspheres, by a fixed 
funnel method. 
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Tan (θ) = height/radius.        [2] 
 
Scanning electron microscopic (SEM) study:   SEM photographs were taken with a scanning 
electron microscope Model Joel- LV-5600, USA, at the required magnification at room 
temperature. The photographs were observed for morphological characteristics and to confirm 
spherical nature of the microspheres.  
 
Determination of the sphericity: To determine the sphericity, the tracings of PEA 
microspheres (magnification 45x) were taken on a black paper using camera Lucida, (Model -
Prism type, Rolex, India) and circulatory factor was calculated [6]. 
 
Drug content:  Uniformity of drug content for the best formulation and their corresponding 
commercial formulation was determined. The content of 5 units were combined and weighed to 
the average weight of each unit. The amount equivalent to the content of each unit was 
determined. In brief, drug was extracted from the respective dosage forms using methanol (80 
%). Methanolic extract was suitably diluted and drug content was determined. The results are 
expressed as percentage claim.  
 
Estimation of drug loading:  Drug incorporated (100 mg) PEA microspheres of each batch 
were selected and powdered in a mortar. Drug from PEA microspheres was extracted using 
methanol (80 %),were filtered and analyzed after necessary dilution. In-vitro studies were carried 
out for all the batches of the prepared formulations and their corresponding commercial 
formulations [7-9]. 
 
Differential scanning calorimetry (DSC):  All dynamic DSC studies were carried out on Du 
Pont thermal analyzer with 2010 DSC module. Calorimetric measurements were made with 
empty cell (high purity alpha alumina discs were used for Indomethacin and Indomethacin and 
high purity gold discs was used for Indomethacin of Du Pont company as the reference. The 
instrument was calibrated using high purity indium metal as standard. The dynamic scans were 
taken in nitrogen atmosphere at the heating rate of 100C/min. The runs were made in triplicate.    
 
Fourier Transform Infrared Radiation Measurements (FT-IR):  FT-IR analysis was carried 
out for pure drug and for microspheres with and without drug using KBr pellet method on FTIR 
spectrophotometer type Shimadzu model 8033, USA.  
 
In Vitro release studies 
USP XXI dissolution apparatus, type II was employed to study the percentage of drug release 
from the prepared formulations. A quantity of drug loaded microspheres (IM equivalent to 75 
mg) were subjected for dissolution study in 900 ml of dissolution medium for 2 h in pH 1.2 
hydrochloric acid and buffer pH 7.2 phosphate buffer. The dissolution media was maintained at 
370C ± 0.50C and stirred at 100 rpm. Drug release from the formulations were determined by 
withdrawing 10 ml of samples using guarded pipette at 30 minutes interval for first four hours 
and one hour interval for the remaining four hours. Samples withdrawn were estimated after 
appropriate dilution. Release studies were carried out in triplicate.     
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Release studies of prepared microspheres were compared to commercially available Microcid 
SR-75 in order to interpret the release pattern required. 
 
In vivo studies   
Subjects:    Four male and four female healthy adult rabbits were included in this study. 
Provisions were made for all observed signs and symptoms occurring during the study period to 
be recorded in full. 
 
Ethical review: Written approval obtained from local ethical committee of Farooqia College of 
pharmacy, Mysore, India.  
 
Study design and doses: Microcid SR-75 capsules coded as product – A and indomethacin 
loaded in PEA polymer microspheres coded as product B. The study was an open, randomized 
complete cross over in which a single 75 mg dose of each product 
(Product A and B) was administered to fasting, healthy adult males and females on two different 
occasions, separated by a wash out period of 2 weeks between dosing.  The content uniformity of 
marketed product and optimized formulation have been estimated as per USP specifications (13). 
Contents of 5 units of Microcid SR-75 capsule and formulation IM1 were individually 
combined and weighed to average weight of each unit.  
 
Procedure:   All the animals were reported to the clinical trial laboratory from animal house at 
7.00 AM after overnight fast of 10 hours. After shaving near the neck, an 18 gauge (1.3 x 45 
mm, 96ml / min) canula was inserted in to a jugular vein and kept with heparinised saline lock 
the ensuing 24 h blood sampling. Test medication products A and B were administered to the 
subjects with banana and 200ml water. A light food was provided at 3rd h followed by two 
standard meals at 7th and 11th h following drug administration. Blood samples (5 ml) were 
collected at 0 h (pre dose), 0.5, 1,1.5, 2, 2.5, 3, 3.5, 4, 5,6, 7, 8, 12, 16, 20, 24 h post dose. Blood 
samples were centrifuged (eltek- TC 4100 D Centrifuge, Elektroshaft, Bombay, India) at 1500 
rpm for 10 min. plasma separated and stored at – 200C prior to analysis.  Any other types of food 
not permitted after 12 h after administration of the test medication. All subjects remained 
ambulatory and strenuous physical activity was prohibited during the first 12h of blood 
sampling. 
 
Chromatographic condition: Serum concentrations of IM were quantified by a modifications   
of the HPLC method described for IM by Johnson et al [10]. 
The mobile phase consisted of 80 % methanol in 0.02M sodium acetate buffer (60: 40 v/v). The 
pH of the acetate buffer was adjusted to pH 3.6 with acetic acid and the mobile phase was filtered 
(0.45 µm pore size) and degassed by sonication under vacuum. The HPLC system was allowed to 
equilibrate at a flow rate of 1ml / min. The column was heated to 400C and the wavelength of the 
detector was set to 320 nm to optimize elution of both IM and MA. MA was used as internal 
standard. The retention time for IM was 5.32 minutes and that for MA (internal standard) was 
8.25 minutes.  
 
Extraction procedure:  Internal standard (100 µl) and citrate buffer (pH 3.0, 500 µl) were added 
to 10ml screw capped glass tubes containing 500 µl of spiked plasma. The samples were 
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extracted gently with 7ml of petroleum ether: Dichloromethane (50: 50) v/v for 5 min on a rotary 
shaker and centrifuged at 600 rpm for 5 min. The organic phase was transferred to 10 ml conical 
test tubes and evaporated to dryness at 400C. The residue was resuspended in 100 µl of mobile 
phase and 25 µl was injected to the column. Quantification was achieved by the measurment of 
the peak area ratio of the indomethacin to the internal standard (mefanamic acid). The limit of 
detection of indomethacin in plasma was 100 ng/ml (500 µl of plasma injected) with a coefficient 
variation (%) ranging between 3.8 - 8. 
 
Statistical Data Analysis:    The pharmacokinetic parameters were calculated using the Quick 
calk, computer PK calculation programmer. The peak plasma concentration (Cmax) and time 
needed to reach peak plasma concentration (Tmax) were computed directly from plasma level 
profiles as a measure of the rate of absorption of the drug from each product. The elimination 
rate constant (Kel) was calculated from the terminal elimination phase of logarithm of drug 
concentrations against time curve by the method of least square regression analysis. The 
biological half life (T1/2) was determined by the relation  T1/2 = 0.693/K. The extent of absorption 
for the products (A&B) in different subjects from the area under the plasma concentration time 
curve from zero to 24 h (AUC 0- 24) was calculated by the trapezoidal rule   method. Area under 
the plasma concentration time curve from zero to infinity (AUC 0 - ∞) was calculated using AUC 0 
- ∞ = AUC 0 -T + C 24 / K. Where C 24 = drug concentrations in the plasma at 24 h. The drug 
plasma concentration and pharmacokinetic parameters were analyzed by analysis of variance 
(ANOVA) at 95% confidence limits. Difference between two related means was considered 
statistically significant when their P values were equal to or less than 0.05. 
 
RESULT AND DISCUSSION 
 
In the present study, a novel dispersed Emulsified Cooling Induced Solidification Method was 
optimized by using inert PEA polymeric materials and nontoxic solvent to entrap the drug. Effect 
of pH on drug loading capacity, effect of surfactant concentration on drug incorporation, drug 
and polymer ratio, stirring sped, and volume of aqueous phase used were optimized during the 
preparation of polymeric microspheres. 
 















IM2 5.2 17.24% 
IM3 6.2 13.72% 
IM4 7.2 11.38% 
 
*Standards are expressed as mean ± SD (n =3) 
 
Loading of drug into PEA polymer was found to be pH dependent. Loading capacity of IM into 
PEA obtained at different pH ranges are given in Table 1. At pH 4.2 (pthalate buffer) a 
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maximum of 22.36 % of IM was loaded which was the maximum amount of drug loading 
encountered in respect to all the formulation. As the pH was increased from 4.2 to 7.2, percent of 
IM loaded was reduced from 22.36 to 11.38 %. It is because when pH value of external phase 
was acidic, solubility of drug was reduced and encapsulated amount of drug was increased. 
 
Incorporation of drug into PEA polymeric microspheres required the addition of a surfactant at 
an optimum concentration to reduce the interfacial tension between the hydrophobic material and 
external aqueous phase. An attempt was made to incorporate liquid drug in the PEA polymer 
microspheres without the addition of a surfactant. But the process failed and resulted in an 
aggregate cake like mass during the solidification of PEA polymer. It may be to repulsion 
resulting from high interfacial tension between the hydrophobic PEA polymer material and 
external aqueous phase.  An optimum concentration of a surfactant to obtain discrete 
microspheres with good flow properties, 1.8 % w/w (Tween-80) for PEA polymer was used. To 
obtain an optimal surfactant concentration, various concentrations ranging from 0.5 to 2.0 % 
(w/w) of the total formulation were tested. Concentrations of surfactant (Tween-80) ranging 
from 0.5 to 1.7 % w/w did not give reproducible microspheres. The resultant PEA polymer 
microspheres were composed of irregular masses and not possible to distinguish as individual 
microspheres. It was found that surfactant having a HLB value of 15 was more suitable to 
increase substantially dispersion of PEA polymer, promote drug incorporation in the 
microspheres.  Solid, discrete, free flowing microspheres were produced, after cooling. A similar 
surfactant concentration was reported for beeswax microspheres prepared by a melt able 




Figure 1. SEM photomicrograph of formulations showing irregular surface and presence of 
drug crystals on microspheres surface 
 
In the present study, to produce spherical discrete microspheres, an optimum of drug to polymer 
ratios is essential. Keeping this in view drug to polymer ratio ranging from 1:4 to 1:1 w/w was 
used, having a formulation code of IM4 to IM1 respectively. A higher amount of drug to 
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polymer ratio is also under taken but it was noticed that when higher amount of drug to PEA 
polymer ratio (2:5) was used, microspheres found to get aggregated and form a mass during the 
cooling process. From the SEM photographs, Figure. 1 it was observed that the prepared 
microspheres were irregular in shape, with surface irregularities and presence of the drug crystals 
on the surface of the microspheres. The presence of drug particles on the surface of the 
microspheres may be due to the sudden diffusion of drug from PEA polymer spheres and 
deposited on the surface at the time of emulsification. The produced microspheres were 
unsuitable for pharmaceutical uses.   
 
In the present study it was found that 150 ml of aqueous phase was suitable for producing 
spherical microspheres. Resultant microspheres obtained using this amount of aqueous phase 
was free from surface irregularities and can be recovered as discrete matter. However an increase 
in amount of aqueous phase and decrease in amount of aqueous phase was also taken into 
consideration to prepare spherical microspheres. It was found that as the volume of external 
phase increased, the yield was reduced and the resultant microspheres were irregular in shape.  
When the volume of the aqueous phase was less than 150 ml, the resultant microspheres were 
found to be aggregated like a mass which is highly impossible to distinguish as a individual and 
discrete microspheres. So in order to avoid the formation of irregularly shaped larger particles, 
and to produce spherical microspheres, in the present method 150 ml of aqueous phase was used.  
 
Temperature of the aqueous phase was maintained at 90ºC. The resultant microspheres were free 
from surface irregularities, except some wrinkles on surface. It was also observed that when the 
temperature of the aqueous phase was less than 90ºC, big flakes were produced. 
 
Another important factor taken into consideration was effect of stirring speed on size distribution 
of drug loaded microspheres. It was observed as the stirring speed was increased considerably, 
reduction with the average size of the microspheres was observed as shown in Table 2. A stirring 
speed of 700 rpm to 1000 rpm was taken into consideration. When the stirring speed was lower 
than 900 rpm, leads to the formation of pellets. Microspheres prepared at different stirring speed 
(700 – 1000 rpm) were prepared and their size was measured by SEM. 
 
From the above results it can be concluded that the drug and PEA ratio, temperature of the 
aqueous phase, surfactant concentration, stirring speed were well controlled to produce better 
quality of microspheres.  
 








Average size (µm)* 
IM1 700 363± 06 
IM2 800 348± 04 
IM3 900 335± 07 
IM4 1000 323± 01 
 
*Standards are expressed as mean ± SD (n =3)  
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Micromeritic properties 
Prepared PEA microspheres were subjected to micromeritic studies and presented in Table 3 
Sieve analysis data indicated that upto 70% of prepared microspheres 132 µm to 796 µm. It was 
observed that an average size of microspheres lies in range between 323 µm to 363 µm. The 
value of angle of repose (θ) were in range between 24.36 ± 2.03 to 28.19 ± 1.29, indicating good 
flowing behavior of prepared microspheres. Measured tapped density lies within range of 0.3541 
± 2.54 to 0.4896 ± 1.41 g/cm3. The percent Carr’s index (%I) was found to be in range 
from11.44 ± 1.51 % to 15.14 ± 3.19 %, suggesting good flow property of the prepared PEA 
microspheres. 
 











IM4 323± 01 80.12 ± 1.03 24.36 ± 2.03 13.53 ± 2.59 0.3854 ± 1.73 
IM3 335± 07 88.33 ± 2.41 25.82 ± 1.13 11.52 ± 1.69 0.3541 ± 2.54 
IM2 348± 04 91.75 ±1.06 27.56 ± 2.34 11.44 ± 1.51 0.4896 ± 1.41 
IM1 363± 06 89.85 ± 1.05 28.19 ± 1.29 15.14 ± 3.19 0.4657 ± 1.10 
*Standards are expressed as mean ± SD (n =3) 
 
The scanning electron micrographic photographs (SEM) were obtained to identify the 
morphology of the prepared PEA microspheres are presented in Figure 2. SEM photographs 
showed that the PEA microspheres were spherical in nature, had a smooth surface with inward 
dents and shrinkage due to the collapse of the wall of the microspheres. Thus the removal of 
solvent from microspheres exerts an influence on the morphology of the end product. These 
characteristics are correlated with waxes microspheres reported earlier by Giannola et al.11SEM 
photographs reveal the absence of drug particles on the surface of microsphere showing uniform 
distribution of the drugs in the walls of the microspheres.   
 
 
Figure 2: SEM photographs of IM loaded PEA microspheres showing spherical shape. 
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Differential Scanning Calorimetry (DSC) and FTIR studies 
To understand the compatible state of the drug, DSC studies were carried out on pure drug, 
microspheres with drug loaded microspheres and without drug; the thermo grams obtained for 
Indomethacin are shown in Figure 3.  The melting point of the PEA polymer was 265 0 C and 
melting point of the drug is 152 to 1690C.  Pure drug exhibits a sharp endothermic peak at to 
1610C. It was observed that absence of the endothermic peak at to 1610C in the drug loaded 
microspheres indicated, that the drug is molecularly distributed in the microspheres.  A 
comparison and interpretation of these results in our study agrees with Tamilvanan et al [12]. 
 
 
Figure 3. DSC thermograms of pure drug IM (Peak a), PEA Polymer (peak b), IM loaded in PEA polymer 
(peak c). 
FTIR spectra showed in Figure 4 revealed that the characteristics peaks of drug occur after 
successful encapsulation, without any change in their position, indicating no chemical 
interactions between the drug and used PEA microspheres. 
 
Encapsulation efficiency 
Encapsulation efficiency (%) of prepared PEA IM microspheres was found to be highest in 
formulation IM1 (92.58%) as compared to IM2 (83.56%), IM3 (76.56%), IM4 (70.27%). This 
effect may be presence of more amount of polymer in IM1 formulation which in turns enhances 
its ability to entrap more amount of drug with in matrices. 
 
161.52 0C, 19.44 cal/g 
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Figure 4. FTIR spectra of Indomethacin and IM loaded PEA microspheres. 
 
In vitro drug release 
From the release studies it was observed that, there is no significant release of drug at gastric pH  
from PEA microspheres and this  indicates that the used PEA were gastro resistant in nature.  
Drug was released in a biphasic manner consisting of initial fast release stage followed by a slow 
release at intestinal pH from PEA microspheres.  Numerical fits indicated that the first order 
release was most appropriate one for describing initial release behavior. The first order release 
gave consistently higher values for the correlation coefficient 0.9922, 0.9856, 0.9751, 0.9854 for 
the prepared formulations. At the end of 8th hour, drug release in the intestinal environment for 
the prepared formulations ranges from 77.81% for IM1 and MIcrosid SR – 75, it was 97.59% as 
shown in Figure 5. The In vitro drug release was considerably retarded from the PEA 
microspheres when compared to marketed product MIcrosid SR – 75. 
 
 
Figure 5.  Drug release profile of Formulation IM4 and marketed product Microsid SR® 75. 
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Initial drug release from PEA microspheres at intestinal environment by biphasic manner and 
associated with an initial burst release of drug, microspheres was observed respectively. This 
release might be from the surface accumulated drug. After initial burst effect, the subsequent 
release of drug was slow and the same behavior of drug from wax was reported by Giannola et al 
[11]. 
 
In the present study, statistically estimated values of n at the 95 % confidence limit, for prepared 
microspheres n = 0.57 and 0.45 indicating fickian transport. This conclusion is agrees with the 
Kumbar et al. have also reported such low values of n for Diclofenac Sodium loaded 
microspheres[13]. 
 
Recovery of the IM from the plasma was calculated by comparison of peak height ratio after 
direct injection of the IM or MA to the peak height of the same concentrations of analytes 
extracted from plasma. In both products the recovery of IM was above 90%. Sensitivity of HPLC 
assay qualitative confirmation of the purity of IM and MA peaks were obtained in Table 4. The 
limit of quantitation was 50 ng/ml of IM in plasma when 0.5 ml plasma was placed. The 
obtained mean correlation coefficients for the standard curves (n=7) was 0.998. Assay was 
shown to be sensitive, capable of detecting IM concentrations in plasma as low as 50 ng/ml. 
Interferences from endogenous compounds were overcome by using as acidic buffer (citrate 
buffer pH 3.0) to alter the pH of the aqueous phase before extraction.  
 





in ng/ml (a) 








% of drug 
recovered c-a 
× 100/b. Mean 
± SDa 
0.5 10 50 54 44 90.0 ± 1.01 
2.0 10 100 106 93 93.0 ± 1.21 
4.0 10 200 209 191 95.0 ± 1.43 
6.0 10 300 303 301 98.7 ± 1.32 
8.0 10 400 405 393 97.4 ± 1.51 
 
In vivo Studies 
In vivo studies were carried out for Microcid®SR capsule (product A) and indomethacin loaded 
PEA microspheres (product B), both containing 75 mg of indomethacin, on adult albino rabbits. 
Blood samples were withdrawn at different time intervals and plasma concentrations  of 
indomethacin was estimated, results of which are presented in Table 5 and the profile is 
presented in Figure 6 for both the products in all the eight subjects. 
 
From the data obtained, it  may be observed that after oral administration, peak plasma 
concentration C max of  2064 ± 55.78 ng/ml was observed after 3.0 hours  for  products A  and   
1939 ± 20.32 ng /ml  for products B. From the comparison of the mean values of plasma 
concentrations of product A and B, it was observed that product B has significantly lower plasma 
concentrations.  But the mean plasma concentrations of indomethacin for both the products in all 
subjects were within the therapeutic concentration range (300- 3000 ng/ml). It was observed that 
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the plasma concentrations of indomethacin in all animals after 24 hours of oral administration 
were below 50 ng/ml for both the products. It was also observed from the studies that the 
therapeutic concentration range of indomethacin maintained for about 12 hours following a 
single oral dose administration for both product A and Product B. From the data obtained, it may 
be observed that the time taken to reach peak plasma concentration Tmax was 3.0 hours for 
product A and 3.5 hours for product B. Though Tmax   was little high for product B, statistical 
significance differences between the two products was not significant. Mean  rate of absorption 
Ka for product A was 0.3822 ± 0.002 h-1  and for product B 0.3668 ± 0.029 h-1 and  mean 
elimination rate constant Kel  for product A  0.2723 ± 0.004 h-1 and for product B 0.2417 ± 0.01 
h-1.  Similarly mean elimination half life t1/2 for products A was 2.65 ± 0.03 h-1 and for product B 
2.86 ± 0.01 h-1 . From the above data it may be observed that Cmax, , and t1/2  for both  products 
differ marginally and statistical difference was not significantly. 
 





Conc. ng/ml  *   
Product B 
Conc. ng/ml *  
     0.5         00.00       00.00 
      1.0 143.62 ± 4.59       00.00 
     1.5 179.62 ± 8.10  138.5 ± 5.09 
     2.0 248.5 ±  8.60  184.62 ± 6.23 
     2.5 1222.5 ± 19.01  900 ± 5.31 
     3.0 2088  ± 50.33 1202.5± 21.63 
     3.5 1976.37 ± 12.72 1928.12 ± 21.30 
     4.0 1400 ± 21.98 1311.25 ± 15.38 
     5.0 900 ± 20.59 806.12 ±1.59 
     6.0 516.87 ± 10.28 471.12 ± 8.85 
     7.0 473.25 ± 13.39 380.62 ± 11.2 
     8.0 342.37 ± 21.81 321.66 ± 6.31 
    12.0 311.62 ± 8.81 205.12 ± 2.32 
    16.0 218.12 ± 11.51 186.12 ± 5.64 
    20.0 154.5 ± 11.16 140.25 ± 9.23 
    24.0 63.87 ± 7.56   65.12 ± 5.24 
*Standards are expressed as mean ± SD (n =3) 
 
The mean AUC0-24 values for products A& B was 9687 ± 132.87 ng/ml. h-1 and 8353 ± 40.04 
ng/ml.h-1.  The systemic availability of indomethacin, as determined by comparison of the area 
under the plasma concentration time curves (AUCs), is lower for both the formulations. The 
reported bioavailability of orally and rectally administered IM is 100% and 80 % relative to 
intravenous dose. As for as comparison of the two formulations are concerned, the statistical 
analysis indicated that the product B exhibited a smaller and non-significant reduction in the AUC 
values. The slower In vitro release of indomethacin from the products A & B may be responsible 
for the decreased AUC values. Statistical analysis indicated that the product B exhibited only a 
smaller and non significant reduction in the AUC values. The observed mean AUC 0- ∞values for 
product A & B was 9860 ± 129.22 ng/ml.h-1 and 8627 ± 46.88 ng/ml.h-1 does not show any 
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significant statistical difference between the products. Comparative profile of various 














Figure 6. Mean plasma concentrations time profiles of product A and product B  
Product A - Microcid®SR and Product B – IM loaded in PEA microspheres.   
 
 
Table 6. Statistical comparison of the mean values of pharmacokinetic parameters   product A & B 
 
Parameters Product A Product B P 
Cmax 2064 ± 55.78 ng /ml 1939 ± 20.32 ng /ml <  0.05 
Tmax 3.0 h 3.5 h <  0.05 
Ka 0.3822 ± 0.002 h-1 0.3668 ± 0.002   h-1 <  0.05 
Kel 0.2723 ± 0.004 h-1 0.2417 ± 0.01 h-1 < 0.05 
t1/2 2.65 ± 0.03 h-1 2.86 ± 0.20 h-1 <  0.05 
AUC 0- 24 9687 ± 132.87 ng/ml h- 8353 ± 40.04 ng/ml h- <  0.05 
AUC 0- ∞ 9860 ± 129.22 ng/ml h- 8627 ± 46.88 ng/ml h- <  0.05 
 
On the basis of FDA recommendation, the two products, Microcid®SR and formulation found to 
be bioequivalent. No untoward effects were observed by any of the subjects after administration 
of either product. 
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CONCLUSION 
 
Present work aimed to prepare and evaluate microspheres loaded with Indomethacin by novel 
dispersed Emulsified Cooling Induced Solidification Method for controlled release of drug. 
Method employed was simple and economical, without using any toxic solvents. Results of drug 
entrapment and micromeritic properties exhibited good results. It was found that microspheres 
prepared were spherical as indicated by SEM studies. Compatibility studies were done by FTIR 
and DSC studies. Results indicate that polymer and drug are compatible with each other. 
Optimized formulation and marketed formulation shows comparable drug release profile. 
Optimized formulation and marketed productMicrocid®SR showed similarity in drug release 
profiles and in vivo bioequivalent behavior. From the present data it is concluded that prepared 
formulation controlled the drug release in a satisfactory fashion, which in turn demonstrate the 
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